Teduglutide
Helps the intestine absorb more nutrients by promoting gut lining growth. Used for short bowel syndrome.
This peptide is an FDA-approved drug product that can be legally prescribed by licensed clinicians.
The basics
- Generic Name
- teduglutide (GLP-2 analog)
- Brand Names
- Gattex
- Regulatory Status
- Prescribed by Doctors
- Therapeutic Areas
- Gastrointestinal
- Prescribing Specialties
- Gastroenterology
Wellness Goals
What it does
Teduglutide is an FDA-approved medication that your doctor can prescribe. GLP-2 analog that promotes intestinal mucosal growth and adaptation by stimulating crypt cell proliferation and inhibiting apoptosis in the intestinal epithelium.
How it's taken
Daily subcutaneous injection
How people access it
Prescribed by gastroenterologists for short bowel syndrome. Specialty pharmacy distribution. Requires REMS enrollment.
What doctors prescribe it for
- Short bowel syndrome in adults dependent on parenteral support
- Short bowel syndrome in pediatric patients 1 year and older dependent on parenteral support
Clinicians may prescribe FDA-approved drugs for off-label uses based on their clinical judgment. Off-label indications have not undergone the same FDA review process as the labeled uses listed above.
How to know it's legit
You can independently verify the FDA-approval status of Teduglutide through these free, publicly available databases:
- DailyMed (dailymed.nlm.nih.gov) — Search for Gattex to find the current FDA-approved labeling, including indications, dosing, warnings, and contraindications.
- Drugs@FDA (accessdata.fda.gov/scripts/cder/daf/) — Search to find the original approval letter, review documents, and approval history.
- FDA Orange Book (orangebook.fda.gov) — Search for therapeutic equivalence evaluations and patent/exclusivity information.
Common Questions
Yes. Teduglutide (Gattex) is an FDA-approved drug product. It has undergone rigorous review of safety, efficacy, and manufacturing quality by the FDA. It can be legally prescribed by licensed clinicians for its approved indications.
Teduglutide is FDA-approved for: Short bowel syndrome in adults dependent on parenteral support; Short bowel syndrome in pediatric patients 1 year and older dependent on parenteral support. Off-label use may be considered by clinicians on a case-by-case basis, but only the labeled indications have been reviewed and approved by the FDA.
You can verify the approval status of Teduglutide through several official FDA resources: DailyMed (dailymed.nlm.nih.gov) for current labeling, Drugs@FDA (accessdata.fda.gov/scripts/cder/daf/) for approval history, and the FDA Orange Book for therapeutic equivalence information. These are free, publicly available databases.
Want to learn more?
Explore how Teduglutide compares to other options, or dive deeper into how FDA approval works.
Explore All Peptides